Woodline Partners’s Monte Rosa Therapeutics GLUE Stock Holding History
Bought
Maintained
Sold
Other funds holding GLUE
BBA
Woodline Partners's GLUE Position: Q3 2026 in Review
Woodline Partners reduced its Monte Rosa Therapeutics (GLUE) stake by 22% in Q3 2026, selling an estimated $3.63M and leaving 750,884 shares worth $8.96M. The position accounts for 0.03% of the portfolio, ranked #588.
Woodline Partners first reported a position in GLUE in Q2 2021 and has held it in 10 quarters since. The position peaked at $23.3M in Q2 2026. 190 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.
- Woodline Partners held 750,884 shares of Monte Rosa Therapeutics worth $8.96M as of Q3 2026.
- Woodline Partners sold 212,000 Monte Rosa Therapeutics shares in Q3 2026, an estimated $3.63M.
- Monte Rosa Therapeutics made up 0.03% of Woodline Partners's portfolio in Q3 2026, its #588 holding.
- Woodline Partners first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 10 quarters since.
- Woodline Partners's Monte Rosa Therapeutics position peaked at $23.3M in Q2 2026.
- 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.
Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.